Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis

Neurology

Volumn 72, Issue 7, 2009, Pages 595-601

  Altmann, D R ^a,b   Jasperse, B ^c   Barkhof, F ^c   Beckmann, K ^d   Filippi, M ^e   Kappos, L D ^f   Molyneux, P ^g   Polman, C H ^c   Pozzilli, C ^h   Thompson, A J ^b   Wagner, K ^d   Yousry, T A ^b   Miller, D H ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d BAYER PHARMA AG   (Germany)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; ATROPHY; BRAIN; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SAMPLE SIZE; TREATMENT OUTCOME;

ADULT; ATROPHY; BRAIN; COHORT STUDIES; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 61849095259     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000335765.55346.fc     Document Type: Article

References (29)

1. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal tran-section in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
2. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000;47:391-395.
3. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128(pt 11):2705-2712.
4. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD. Transected neuritis, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
5. Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676-1695.
6. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-1704.
7. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-la for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364: 1489-1496.
8. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390-1401.
9. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;119:2009-2019.
10. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000;123:2256-2263.
11. Stevenson VL, Smith SM, Matthews PM, Miller DH, Thompson AJ. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. J Neurol 2002;249:171-177.
12. Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466-475.
13. Jasperse B, Valsasina P, Neacsu V, et al. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. J Magn Reson Imaging 2007;26:881-885.
14. Smith SM, Zhang YY, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-489.
15. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1):208-219.
16. Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 1992;11:1685-1704.
17. Goldstein H. Multilevel Statistical Models. Kendall's Library of Statistics Series 3. London: Hodder Arnold; 1995.
18. Carpenter JR, Bithall JF. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000;19:1141-1164.
19. Schott JM, Frost C, Whitwell JL, et al. Combining short interval MRI in Alzheimer's disease: implications for therapeutic trials. J Neurol 2006;253:1147-1153.
20. Frost C, Kenward MG, Fox NC. The analysis of repeated "direct" measures of change illustrated with an application in longitudinal imaging. Stat Med 2004;23:3275-3286.
21. Anderson VM, Bartlett JW, Fox NC, Fisniku L, Miller DH. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. J Neurol 2007;254:1588-1594.
22. Anderson VM, Fernando KT, Davies GR, et al. Cerebral atrophy measurement in clinically isolated syn-dromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods. J Neuroim-aging 2007;17:61-68.
23. Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004;62:1432-1434.
24. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310.
25. Armitage P, Berry G, Matthews J. Statistical Methods in Medical Research, 4th ed. Oxford: Blackwell Science; 2002.
26. Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002;59:1572-1576.
27. Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-1795.
28. Rao AB, Richert N, Howard T, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 2002;59:688-694.
29. Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005;64:236-240.